Monday, October 26, 2026
ExploreSearch
Via News
Via News Knowledge File

Elon Musk

person80% conf.·synced Oct 26, 2026

Entrepreneur known for concentrated portfolio approach

41
sourced metrics
1064
relationships
20
stated objectives
8
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Net Worth As Pct Of Us Gdp
3percent
source
Ownership Stake Tesla
10percent
source
Social Media Post Views
68000000views
source
Social Media Post Likes
195000likes
source
Social Media Post Comments
46000comments
source
Ai Compute Output Worldwide
20gigawatts_per_year
source
Ownership Stake Spacex
38percent
source
Voting Power Pct
85percent
source
Cash
38USD
source
Voting Control
85percent
source
Compensation
44.9USD
source
Compensation Value
1000billion_USD
source
Market Cap
1000000000000USD
source
Market Share
42percent
Aug 16, 2026source
Net Worth
1000USD
Jul 27, 2026source
Net Worth Sensitivity Per Dollar Spacex
4.76USD
Jun 23, 2026source
Parameter Count
10votes_per_Class_B_share
Jun 17, 2026source
Shares Owned Spacex
4760000000shares
Jun 1, 2026source

Stated objectives

Get $1 trillion from Tesla

source
target: 1000000000000 stated

Deliver on promises for Tesla robotaxi and Optimus humanoid robot

source
stated

Send rockets to Mars regularly before taking SpaceX public (historical objective)

source
stated

Colonize Mars using SpaceX Starship and associated infrastructure

source
stated

Reduce the size of the US government so Americans can keep more of their earned income

source
stated

Reduce the size of the US government so citizens can keep more of their hard-earned money

source
stated

Increase ownership stake in Tesla to mid-20s percentage for voting control

source
target: 28 percent by 2034-11-06 00:00:00stated

Deliver transformational performance through operational breakthroughs, innovation, and value creation to earn 2025 CEO Performance Award

source
target: extraordinary milestones required for any payout stated

Achieve Level 5 autonomy for Tesla vehicles

source
stated

Own physical assets like real estate and stocks instead of cash during high inflation

source
stated

Relationship graph · 1064 connections

founded
394
Employs
380
Owns
107
Competes with
26
Covered by
15
lawsuit
14
Developed by
12
Invested in
11
Invested in
Dogecoin
Covered by
The Hill

Via News coverage

SPCQ Targets -200% SpaceX Returns, But Daily Rebalancing Can Erase Correct Bearish Bets
June 23, 2026
NVIDIA's Computer Vision Push Drives Physical AI Deployment Wave Across Infrastructure and Autonomous Systems
March 21, 2026
NVIDIA Secures Salesforce, Adobe, Siemens for Agent Toolkit as LeCun Raises $1B+ in Competitive AI Push
March 19, 2026
Tesla Q4 2025: EV Sales Drop as Musk Pivots to Autonomous Robotaxi
February 3, 2026
Tesla's Strategic Shift: Model S and X Production Plans Under Scrutiny
January 30, 2026
Musk vs. O'Leary: Prediction Markets Bet on Airline-Tech Tensions
January 20, 2026
Judge Weighs Contempt Charges Against Elon Musk Over Tweet; Lawsuit Against OpenAI Proceeds
January 8, 2026
Tesla's Recent Slide Tests Investor Patience Amid Strong Track Record
January 5, 2026
This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com